Pieris Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
Pieris Pharmaceuticals Il CEO è Steve Yoder, nominato in Dec2014, e ha un mandato di 9.92 anni. la retribuzione annua totale è $ 1.36M, composta da 43% di stipendio e 57% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.006% delle azioni della società, per un valore di $ 1.30K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.2 anni e 7 anni.
Informazioni chiave
Steve Yoder
Amministratore delegato
US$1.4m
Compenso totale
| Percentuale dello stipendio del CEO | 43.0% |
| Mandato del CEO | 9.9yrs |
| Proprietà del CEO | 0.006% |
| Durata media del management | 5.2yrs |
| Durata media del Consiglio di amministrazione | 7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$585k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$2m | US$565k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$548k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$535k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$515k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$3m | US$500k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$1m | US$450k | -US$18m |
Compensazione vs Mercato: La retribuzione totale di Steve ($USD 1.36M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 655.65K ).
Compensazione vs guadagni: La retribuzione di Steve è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Steve Yoder (48 yo)
9.9yrs
Mandato
US$1,358,952
Compensazione
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$1.36m | 0.0057% $ 1.3k | |
| Senior VP | 5.2yrs | US$729.04k | 0.018% $ 4.2k | |
| Executive Director of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Supply Chain Officer | 5.1yrs | Nessun dato | Nessun dato |
5.2yrs
Durata media
48yo
Età media
Gestione esperta: Il team dirigenziale di PIRS è esperto e expertise (durata media dell'incarico 5.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$1.36m | 0.0057% $ 1.3k | |
| Independent Chairman | 7.5yrs | US$94.09k | 0.019% $ 4.3k | |
| Independent Director | 9.9yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 8.2yrs | US$72.58k | 0.019% $ 4.3k | |
| Independent Director | 6.2yrs | US$65.08k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$53.09k | 0% $ 0 | |
| Independent Director | 6.6yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$52.09k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Clinical & Scientific Advisory Board | no data | Nessun dato | Nessun dato |
7.0yrs
Durata media
61.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PIRS sono considerati esperti (durata media dell'incarico 7 anni).